---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063539"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T18:16:23.319627+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Q1 net loss $77M; cash runway into 2029, RLY-2608 Phase 3 on track

## Summary
- Net loss $77.1M ($0.46/share) vs $81.4M ($0.62/share) in Q1 2024; revenue $7.7M from Elevar license completion.
- Cash $710.3M; runway extended into 2029, funding ReDiscover-2 past topline and vascular malformations proof-of-concept.
- Phase 3 ReDiscover-2 trial of RLY-2608+fulvestrant in breast cancer on track for mid-2025; ASCO abstract accepted.
- Initiated Phase 1 RLY-2608 vascular malformations trial in Q1 2025.
- Reduced workforce by ~70; research run rate cut ~80%; out-licensed RLY-4008 to Elevar with downstream economics.

## SEC filing metadata
- accession: 0000950170-25-063539
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017025063539/0000950170-25-063539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017025063539/rlay-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063539
- JSON: https://secwatch.observer/filing/0000950170-25-063539.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063539.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.